Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden

BACKGROUND: Pathological complete response (pathCR) in rectal cancer is beneficial, as up to 75% of patients do not experience regrowth of the primary tumour, but it is poorly understood. We hypothesised that the changes seen in the pre-treatment biopsies of pathCR but not seen in residual tumour af...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockton, Joanne D., Tee, Louise, Whalley, Celina, James, Jonathan, Dilworth, Mark, Wheat, Rachel, Nieto, Thomas, Geh, Ian, Barros-Silva, João D., Beggs, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278688/
https://www.ncbi.nlm.nih.gov/pubmed/34256782
http://dx.doi.org/10.1186/s13014-021-01853-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278688/
https://www.ncbi.nlm.nih.gov/pubmed/34256782
http://dx.doi.org/10.1186/s13014-021-01853-y

Ejemplares similares